Recent News for SRPT - Sarepta Therapeutics, Inc.

Date Title
Aug 19 Sarepta Dives After FDA Rejects Its Newest Muscular Dystrophy Drug
Aug 19 UPDATE 1-U.S. FDA declines to approve Sarepta's second Duchenne treatment
Aug 19 FDA rejects Sarepta's second Duchenne drug
Aug 19 Sarepta -13% on FDA concerns about muscular dystrophy drug
Aug 19 Sarepta stock falls on FDA concerns about drug
Aug 19 Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
Aug 19 Notable Insider Buys In The Past Week: General Electric, Symantec And More
Aug 19 Solid Biosciences Surges on DMD Gene Therapy Study Amendments
Aug 18 Weekly CEO Buys Highlight
Aug 17 The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week
Aug 17 Stocks To Watch: Eyes On Jackson Hole, Lyft And Disney D23
Aug 16 Key events next week - healthcare
Aug 16 Gene therapies to test FDA's approach to regulating drugs after launch, experts say
Aug 15 Sarepta to launch late-stage study of high-dose eteplirsen
Aug 14 Xontogeny, accelerator launched by former Sarepta CEO, preps five new biotechs
Aug 13 Sarepta Therapeutics - Buy The Latest 'Bad News'
Aug 12 Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares
Aug 9 Why Sarepta Therapeutics Stock Tanked on Thursday
Aug 9 Sarepta Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Aug 9 110 Biggest Movers From Yesterday
Aug 8 Why Zillow Group, Sarepta Therapeutics, and CenturyLink Slumped Today
Aug 8 Sarepta stock tumbles after Duchenne gene therapy complication
Aug 8 This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
Aug 8 Sarepta stock drops on erroneous adverse event report to FDA
Aug 8 Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)
Back to the Main SRPT Page...